Advertisement

Anticoagulants, Antiplatelets, and Thrombolytics

  • Shaker A. Mousa

Part of the Methods In Molecular Medicine™ book series (MIMM, volume 93)

Table of contents

  1. Front Matter
    Pages i-x
  2. Owen J. T. McCarty, James P. Abulencia, Shaker A. Mousa, Konstantinos Konstantopoulos
    Pages 21-34
  3. Shaker A. Mousa
    Pages 49-59
  4. Walter P. Jeske, Jeanine M. Walenga
    Pages 61-82
  5. Margaret Prechel, Walter P. Jeske, Jeanine M. Walenga
    Pages 83-93
  6. Jeanine M. Walenga, Walter P. Jeske, Debra Hoppensteadt, Jawed Fareed
    Pages 95-117
  7. Shaker A. Mousa
    Pages 119-132
  8. Shaker A. Mousa, Jawed Fareed, Omer Iqbal, Brigitte Kaiser
    Pages 133-155
  9. Shaker A. Mousa
    Pages 157-174
  10. Ronald J. Shebuski, Larry R. Bush, Alison Gagnon, Liguo Chi, Robert J. Leadley Jr.
    Pages 175-219
  11. Walter P. Jeske, Omer Iqbal, Jawed Fareed, Brigitte Kaiser
    Pages 221-237
  12. Shaker A. Mousa
    Pages 239-246
  13. Shaker A. Mousa
    Pages 247-251
  14. Hikmat Abdel-Razeq, Mohamad Qari, Jorgen Kristensen, Hussein Alizeidah, Faisal Al-Sayegh, Mahmoud Marashi et al.
    Pages 267-292
  15. Back Matter
    Pages 293-307

About this book

Introduction

During the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and invention highlight the latest developments in antithrombotics and provide experimental methods for the discovery of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP-receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue-factor targeting, platelet-receptor targeting, and antithrombin III modulation. The authors also define the clinically relevant in vitro and in vivo models of thrombosis and hemostasis that led to these advances and that will surely aid in the discovery of the next generation of antithrombotics.
Up-to-date and forward-looking, Anticoagulants, Antiplatelets, and Thrombolytics illuminates the latest developments in the field of thrombosis and provides both basic and clinical investigators a broad array of successful experimental methods for the discovery and development of novel drugs to treat thrombotic and cardiovascular diseases.

Editors and affiliations

  • Shaker A. Mousa
    • 1
  1. 1.Albany College of PharmacyAlbany

Bibliographic information

  • DOI https://doi.org/10.1385/1592596584
  • Copyright Information Humana Press 2004
  • Publisher Name Springer, Totowa, NJ
  • eBook Packages Springer Protocols
  • Print ISBN 978-1-58829-083-0
  • Online ISBN 978-1-59259-658-4
  • Series Print ISSN 1543-1894
  • Series Online ISSN 1940-6037
  • Buy this book on publisher's site